Description: Aethlon Medical, Inc., a medical device company, focuses on creating devices for the treatment of cancer, infectious diseases, and other life-threatening conditions. It develops Aethlon Hemopurifier, a medical device that targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The company's Aethlon Hemopurifier addresses antiviral drug-resistance in hepatitis-C virus and human immunodeficiency virus infected individuals; serves as a countermeasure against viral pathogens not addressed by drug or vaccine therapies; and represents the therapeutic strategy to address cancer promoting exosomes. It is also developing exosome-based products to diagnose and monitor neurological disorders and cancer; and a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that often results in the death of combat-injured soldiers. The company was founded in 1991 and is based in San Diego, California.
Home Page: www.aethlonmedical.com
AEMD Technical Analysis
11555 Sorrento Valley Road
San Diego,
CA
92121
United States
Phone:
619 941 0360
Officers
| Name | Title |
|---|---|
| Dr. Charles J. Fisher Jr., M.D. | CEO, Director & Member of Extracorporeal Therapy Advisory Board |
| Mr. Steven P. Larosa M.D. | Chief Medical Officer & Acting Chief Scientific Officer |
| Mr. Guy F. Cipriani BS (Eng.), MBA | Sr. VP, Chief Bus. Officer & Director |
| Mr. James B. Frakes M.B.A. | CFO, Sr. VP of Fin. & Sec. |
| Mr. Sunil Sawhney | Head of Clinical Studies |
| Dr. Richard H. Tullis Ph.D. | Consultant |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Equipment & Supplies |
| GIC Sub-Industry: | Health Care Equipment |
| Forward PE: | 0.2102 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4273 |
| Price-to-Sales TTM: | 228.4526 |
| IPO Date: | 2001-01-02 |
| Fiscal Year End: | March |
| Full Time Employees: | 14 |